If you would like to ask our webinar guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

 

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCLIN.L Share News (CLIN)

  • There is currently no data for CLIN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Kibo invests in Eqtec project; Clinigen falls

Thu, 16th Sep 2021 10:55

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

----------

AIM - WINNERS

----------

Galileo Resources PLC, up 20% at 1.32 pence, 12-month range 0.61p-2.80p. The miner, with projects in Botswana, Zambia and South Africa, says all conditions for licence sale agreement with ASX-listed Sandfire Resources Ltd have been met. Completion of deal set for September 22. The deal, first announced in January, will see Sandfire pay USD1.5 million in cash for nine Kalahari copper belt licences.

----------

Kibo Energy PLC, up 16% at 0.26 pence, 12-month range 0.16p-0.56p. The Africa- and UK-focused energy company will acquire just under a 55% stake in the proposed Billingham waste gasification and power plant in Teesside, UK. Fellow AIM listing Eqtec PLC will retain just under over a 45% stake. Kibo's initial funding contribution will amount to GBP3 million. Eqtec shares were 2.4% lower.

----------

AIM - LOSERS

----------

Clinigen Group PLC, down 9.7% at 632.14 pence, 12-month range 554.00p-891.79p. Staffordshire-based pharmaceuticals and services provider lowers its earnings before interest, tax, depreciation and amortisation growth outlook for the new financial year. It now expects Ebitda growth between 5% and 10%. Clinigen anticipates lower sales of the Erwinase cancer treatment. Double-digit growth was previously expected. In the year ended June 30, revenue rose 12% to GBP523.6 million from GBP466.7 million. Pretax profit more than doubled to GBP51.8 million from GBP23.2 million.

----------

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
14 Jul 2020 09:07

Clinigen FY revenues continue to rise, profit growth slowed by Covid-19

(Sharecast News) - Pharmaceutical group Clinigen warned full-year profit growth would be at the lower end of guidance as a result of the Covid-19 pandemic and the launch of a low-cost competitor to its Foscavir drug.

Read more
13 Jul 2020 16:29

Clinigen gets orphan drug designation for 'aldesleukin' in the US

(Sharecast News) - Pharmaceutical services company Clinigen Group announced on Monday that the US Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) has granted orphan drug designation for 'aldesleukin', in the treatment of amyotrophic lateral sclerosis (ALS).

Read more
13 Jul 2020 13:48

Monday broker round-up

(Sharecast News) - Kingfisher: RBC Capital Markets reiterates outperform with a target price of 275.0p

Read more
13 Jul 2020 08:41

Clinigen Gets US Orphan Drug Designation For ALS Treatment Aldesleukin

Clinigen Gets US Orphan Drug Designation For ALS Treatment Aldesleukin

Read more
14 Jun 2020 19:22

Sunday newspaper round-up: Two meters, Rolls Royce, Clinigen

(Sharecast News) - Senior scientists have reported flaws in an influential World Health Organization-commissioned study into the risks of coronavirus infection and say it should not be used as evidence for relaxing the UK's 2-metre physical distancing rule. Critics of the distancing advice, which states that people should keep at least 2 metres apart, believe it is too cautious. They seized on the research commissioned by the WHO, which suggested a reduction from 2 metres to 1 would raise infection risk only marginally, from 1.3% to 2.6%. - Guardian

Read more
28 May 2020 13:34

Thursday broker round-up

(Sharecast News) - Provident Financial: RBC Capital Markets reiterates sector performer with a target price of 195p.

Read more
28 May 2020 09:37

UK BROKER RATINGS SUMMARY: Jefferies Initiates Greggs, Games Workshop

UK BROKER RATINGS SUMMARY: Jefferies Initiates Greggs, Games Workshop

Read more
26 May 2020 17:50

Clinigen Chair Leaves Audit Committee After Shareholder Engagement

Clinigen Chair Leaves Audit Committee After Shareholder Engagement

Read more
12 May 2020 10:37

McCarthy & Stone CFO Rowan Baker Defects To Laing O'Rourke

McCarthy & Stone CFO Rowan Baker Defects To Laing O'Rourke

Read more
16 Apr 2020 12:00

Clinigen Says Annual Trading In Line; Signs Erwinase License Agreement

Clinigen Says Annual Trading In Line; Signs Erwinase License Agreement

Read more
24 Mar 2020 16:00

DIRECTOR DEALINGS SUMMARY: Pearson And IHG Chairs Buy Amid Virus Pain

DIRECTOR DEALINGS SUMMARY: Pearson And IHG Chairs Buy Amid Virus Pain

Read more
20 Mar 2020 09:49

UK BROKER RATINGS SUMMARY: BHP Gets Upgrades From JPMorgan, Deutsche

UK BROKER RATINGS SUMMARY: BHP Gets Upgrades From JPMorgan, Deutsche

Read more
18 Mar 2020 13:42

Wednesday broker round-up

(Sharecast News) - Polypipe: Deutsche Bank upgrades to buy with a target price of 550p.

Read more
12 Mar 2020 16:05

UK Dividends Calendar - Next 7 Days

UK Dividends Calendar - Next 7 Days

Read more
11 Mar 2020 13:37

Wednesday broker round-up

(Sharecast News) - Clinigen Group: Liberum upgrades to buy with a target price of 780.0p.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.